Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)
Status:
Terminated
Trial end date:
2018-02-09
Target enrollment:
Participant gender:
Summary
This is a multicenter, double-blind, Phase 2b, long-term extension (LTE) to the ADDRESS II
core trial (EMR 700461-023) (NCT01972568), to evaluate long-term safety and tolerability of
atacicept in participants with systemic lupus erythematosus (SLE). Participants who completed
the 24-week core study ADDRESS II core study (NCT01972568) and thus not met any of the
discontinuation criteria were invited to enter this long-term extension (LTE) study
NCT02070978.